Skip to main content
Premium Trial:

Request an Annual Quote

VelaDx, Thomas Jefferson Co-developing MDx for Cancer, Infectious Diseases

NEW YORK (GenomeWeb News) – Vela Diagnostics today announced a deal with Thomas Jefferson University and Hospitals to jointly develop molecular diagnostics aimed at cancer and infectious diseases.

The Singapore-based company said the two partners are currently deciding on several projects, including developing next-generation- and PCR-based assays. Using new technologies, Thomas Jefferson will help VelaDx develop and validate the assays. VelaDx will seek regulatory approval for the assays on a global basis.

"Partnering with Jefferson provides Vela Diagnostics with access to world-recognized experts in the molecular diagnostics industry," Michael Tillmann, CEO of VelaDx, said in a statement. "This is essential for the development of high quality molecular diagnostic assays in a dynamic clinical environment."

Terms of the deal were not disclosed.

VelaDx develops molecular diagnostics based on its Sentosa workflow system. In October, VelaDx and Life Technologies announced a deal under which VelaDx would develop clinical diagnostic tests on Life Tech's Ion Personal Genome Machine.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.